I wanted to share this since all men if they live long enough will develop prostate cancer.
The FDA has approved darolutamide (Nubeqa) — a novel androgen-receptor inhibitor — to treat nonmetastatic, castration-resistant prostate cancer (cancer that continues to progress despite very low testosterone levels).
Approval was based on a phase 3 clinical trial, published in the New England Journal of Medicine, among men already receiving androgen deprivation therapy. Those randomized to add darolutamide had a median metastasis-free survival of 40 months, versus 18 months among those who added placebo.